Jstar Capital Investments
Emerging managerBuilt from this firm's Form D filings. The firm files no SEC adviser report.
- Website
- https://jstarinvestments.com
- HQ
- TX
Jstar Capital Investments focuses on breakthrough med-tech solutions and treatments across cardiovascular, orthopedic and biopharma innovation. Its co-founders are Evan Pritchard and Jared Leger. Portfolio companies named include Sonavex, OsteoCentric, Emblok, Egg Medical and Significo, working on dialysis monitoring, bone-integrating implants, aortic embolic protection, radiation shielding, and health AI.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Not stated | Not enough dated deals |
| Sectors | Healthtech, Biotech, Medical devices | Not enough dated deals |
| Regions | Global | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| JStar Capital Investments VII, LLC JSTAR Capital Investments backs breakthrough med-tech solutions and treatments across cardiovascular, orthopedic and biopharma innovation. It targets unmet clinical needs, backs experienced leadership ahead of key inflection points, and prioritizes capital-efficient businesses with clear milestones. Inferred from the firm's website | 2026 | $7.63M to $7.63M (Form D) | Raising |
| JStar Capital Investments III, LLC JSTAR Capital Investments backs breakthrough med-tech solutions and treatments across cardiovascular, orthopedic and biopharma innovation. It targets unmet clinical needs, backs experienced leadership ahead of key inflection points, and prioritizes capital-efficient businesses with clear milestones. Inferred from the firm's website | 2025 | $2.82M to $5.5M (Form D) | Open, writing first checks |
| JStar Capital Investments IV, LLC JSTAR Capital Investments backs breakthrough med-tech solutions and treatments across cardiovascular, orthopedic and biopharma innovation. It targets unmet clinical needs, backs experienced leadership ahead of key inflection points, and prioritizes capital-efficient businesses with clear milestones. Inferred from the firm's website | 2024 | $25.28M to $25.4M (Form D) | Open, writing first checks |
| JStar Capital Investments I, LLC JSTAR Capital Investments backs breakthrough med-tech solutions and treatments across cardiovascular, orthopedic and biopharma innovation. It targets unmet clinical needs, backs experienced leadership ahead of key inflection points, and prioritizes capital-efficient businesses with clear milestones. Inferred from the firm's website | 2024 | $500K to $6M (Form D) | Open, writing first checks |
03 · People across funds
- Evan Pritchard, Manager of Manager of Issuer
JStar Capital Investments VII, LLC (Named on Form D); JStar Capital Investments III, LLC (Named on Form D); JStar Capital Investments IV, LLC (Named on Form D); JStar Capital Investments I, LLC (Named on Form D)
- Jared Leger, Manager of Manager of Issuer
JStar Capital Investments VII, LLC (Named on Form D); JStar Capital Investments III, LLC (Named on Form D); JStar Capital Investments IV, LLC (Named on Form D); JStar Capital Investments I, LLC (Team)
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://jstarinvestments.com
- https://jstarinvestments.com/contact
- https://jstarinvestments.com/portfolio
- https://jstarinvestments.com/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026